OakChart

Nanobiotix ADR

NBTXHealthcare·Biotechnology·France·Small·NASD·Nov 11 • 3:59 PM ET

32.95+0.08 (0.24%)
2026-11-12 05:01 CET
Market cap
1,678.65 USD m
Revenue, TTM
9.75 USD m
Net income, TTM
-61.66 USD m
Free cash flow, TTM
-48.27 USD m
EPS diluted, TTM
-1.27
P/E
-
Compare

Price

NBTX against its 20, 50 and 200-day averages
2050200miss
20.0030.0040.0050.00284K567KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NBTXclose 32.9520-day 29.1650-day 30.71200-day 34.2232.9552w high52w low

42.3% under the 52-week high of 57.14 on 14 May 2026. 52-week low 19.14 on 26 Nov 2025. Last 15 sessions, 30.0% high to low

Volume 0.40× normal · the line is the 50-bar volume average

Profile

NBTX
52-week range, 36% of the way up
19.1457.14

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Levy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Employees97
IPODec 11, 2020
Beta0.85
ATR, 14d2.13
Rel volume0.40
Short float0.41%
Insider own18.09%
Inst own0.34%

Snapshot

6 groups

Valuation

Index-
Market Cap1.68B
Enterprise Value1.67B
Income-61.66M
Sales9.75M
Book/sh-0.75
Cash/sh2.49
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees97
IPODec 11, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S172.18
P/B-
P/C13.24
P/FCF-
EV/EBITDA-
EV/Sales171.68
Quick Ratio1.44
Current Ratio1.44
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.27
EPS next Y-0.22
EPS next Q-
EPS this Y-5.10%
EPS next Y63.86%
EPS next 5Y-
EPS past 3/5Y30.98% 18.47%
Sales past 3/5Y- 257.86%
EPS Y/Y TTM-58.83%
Sales Y/Y TTM-
EPS Q/Q-559.84%
Sales Q/Q-84.39%
EarningsSep 24 AMC
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own18.09%
Insider Trans0.00%
Inst Own0.34%
Inst Trans4.92%
ROA-61.74%
ROE-
ROIC-131.02%
Gross Margin-
Oper. Margin-392.06%
Profit Margin-632.55%
SMA2013.00%
SMA507.28%
SMA200-3.72%
Trades-

Technical

Shs Outstand50.80M
Shs Float41.73M
Short Float0.41%
Short Ratio1.08
Short Interest0.17M
52W High57.14 -42.33%
52W Low19.14 72.15%
Volatility6.18% 6.61%
ATR (14)2.13
RSI (14)59.34
Beta0.85
Rel Volume0.40
Avg Volume158.20K
Volume63,913

Performance

Perf Week10.94%
Perf Month53.33%
Perf Quarter-13.68%
Perf Half Y-36.68%
Perf YTD42.52%
Perf Year57.50%
Perf 3Y463.25%
Perf 5Y237.95%
Perf 10Y-
Recom1.25
Target Price55.66
Prev Close32.87
Price32.95
Change %0.24%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Sep 15, 2026ResumedGGuggenheimBuy$64+94.2%
Feb 06, 2026InitiatedTTD CowenBuy
Aug 28, 2024InitiatedGGuggenheimBuy$12-63.6%
Dec 08, 2023InitiatedLLeerink PartnersOutperform$11-66.6%
Jan 06, 2021InitiatedEEvercore ISIOutperform

Peers

Mkt cap
TickerCompanyMkt cap
DRTSAlpha Tau Medical Ltd1.30B
BCAXBicara Therapeutics Inc699.06M
KURAKura Oncology Inc687.66M
REPLReplimune Group Inc2.06B
TLXTelix Pharmaceuticals Ltd ADR3.31B
PDSBPDS Biotechnology Corp107.11M
IMTXImmatics N.V1.00B
CGEMCullinan Therapeutics Inc730.42M
JNJJohnson & Johnson675.03B
LNTHLantheus Holdings Inc6.64B

Held by

AUM
TickerCompanyAUM
APIEActivePassive International Equity ETFAUM: 1.13B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-09-24-0.485-0.485-0.8181.731.731
2025S22026-03-31-0.4490.303-0.4486.6051.354
2025S12025-09-30-0.124-0.247-0.12430.9323.902
2024Q42025-04-02-1.111-0.555-0.850-18.7112.122
2024S12024-09-18-0.500-0.512-0.50210.1110.351
2023S22024-04-24-0.311-0.809-0.29535.250.001
2023Q22023-09-26-0.850-0.832-0.8503.491.461
2026S2--0.057--26.643
2027S1--0.101--52.893
2027S2---0.098--39.373

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-1.157-1.444-1.16238.7921.28
2024FY-1.601-1.105-1.559-8.0021.39
2025FY-0.581-0.198-0.57537.8846.28
2026FY--0.611--29.12
2027FY--0.221--69.95
2028FY-0.508--108.1
2029FY-0.201--100.35
2030FY-1.076--167.05

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-10-2330226.645.0248.69
2026S2S2026-10-2230126.935.0249.55
2026S2S2026-09-2530226.935.0249.55
2026S2S2026-09-1410026.5426.5426.54
2026S2S2026-08-2810049.9749.9749.97
2026S2S2026-07-2920039.1628.3549.97
2026S2S2026-07-2020139.1628.3549.97
2026S2S2026-07-1030141.3628.3549.97
2026S2S2026-06-1550131.335.8149.97
2026S2S2026-06-0250331.335.8149.97
2026S2S2026-05-2950331.315.8149.97
2026S2S2026-05-2050331.275.8149.78
2026S2S2026-05-1540332.005.8149.78
2026S2S2026-04-2140246.595.81108.12

Estimate history

EPS, annual-1.692-1.825-2.634-1.57-1.6-1.72-1.162-1.559-0.566
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual0.2840.1370.0760.0570.012032.496-12.55733.454
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual19.62519.6222.39934.41934.8134.85447.11147.40548.388
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue9.7533.45-12.5632.500.000.010.060.080.14
Cost of Goods Sold Incl. D&A----1.58----
Gross Profit-----1.58----
Selling, General and Administrative Excl. Other45.1947.2264.3163.5351.4557.0342.3553.0938.90
Research and Development23.0324.8242.6140.1133.0834.5526.1432.2424.02
Other Operating Expense0.910.02-0.010.180.050.000.050.060.00
Operating Income-38.22-15.61-78.61-32.85-53.07-58.87-44.34-55.06-39.44
Interest Expense24.1711.758.758.636.130.795.715.361.00
Unusual Expense74.6372.23139.545.331.046.400.000.06-
Net Income Before Taxes-65.27-30.22-77.16-47.05-64.24-58.50-40.48-59.71-39.63
Income Taxes-3.61-3.18-3.46-4.13-4.29-2.94-2.19-2.72-3.84
Consolidated Net Income-61.66-27.04-73.70-42.92-59.95-55.56-38.29-56.99-35.80
Net Income From Continuing Operations-61.66-27.04-73.70-42.92-59.95-55.56-38.29-56.99-35.80
Net Income-61.66-27.04-73.70-42.92-59.95-55.56-38.29-56.99-35.80
EPS (Recurring)-0.190.490.51-1.06-1.70-1.47-1.57-2.63-1.82
EPS (Basic, Before Extraordinaries)-1.27-0.57-1.56-1.16-1.72-1.60-1.57-2.63-1.82
EPS (Diluted)-1.27-0.57-1.56-1.16-1.72-1.60-1.57-2.63-1.82
EBITDA-36.35-13.79-76.86-31.21-51.49-57.02-42.34-53.08-38.77
Non-Operating Income (Expense)71.7569.37149.74-0.24-4.007.569.570.780.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.633.003.492.562.502.782.303.341.47
Price To Sales Ratio189.0533.05-8.27-23,802.477,059.21--
Operating Margin-392.06-46.66626.04-101.09--498,011.96-77,783.62-72,341.09-28,818.96
Net Margin-632.55-80.83586.89-132.08--470,022.41-67,179.67-74,874.91-26,159.48
Shares Outstanding50.8048.3947.4047.1134.8534.8134.4222.4019.62
Market Capitalization1,678.651,678.65135.21342.97127.72281.97568.04575.96-

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S12023S22023S12022S22022S1
Total Revenue4.255.5027.236.6632.520.000.000.00
Cost of Goods Sold Incl. D&A-----0.800.760.81
Gross Profit------0.80-0.76-0.81
Selling, General and Administrative Excl. Other25.8919.3027.6234.4033.3730.1623.8327.78
Research and Development13.619.4215.2023.0321.5018.6115.7417.41
Other Operating Expense0.580.34-0.300.230.160.02-0.030.07
Operating Income-23.13-15.09-0.98-28.81-1.86-30.98-24.57-28.67
Interest Expense16.977.194.634.174.514.123.152.98
Unusual Expense0.0074.630.010.135.34-0.010.031.05
Net Income Before Taxes-42.20-23.07-7.64-26.01-14.95-32.09-34.17-29.93
Income Taxes-2.20-1.40-1.76-2.37-2.40-1.73-3.07-1.14
Consolidated Net Income-40.00-21.67-5.88-23.64-12.55-30.36-31.10-28.79
Net Income From Continuing Operations-40.00-21.67-5.88-23.64-12.55-30.36-31.10-28.79
Net Income-40.00-21.67-5.88-23.64-12.55-30.36-31.10-28.79
EPS (Recurring)-0.820.63-0.12-0.50-0.21-0.87-0.89-0.81
EPS (Basic, Before Extraordinaries)-0.82-0.45-0.12-0.50-0.30-0.87-0.89-0.83
EPS (Diluted)-0.82-0.45-0.12-0.50-0.30-0.87-0.89-0.83
EBITDA-22.21-14.14-0.10-27.96-1.02-30.18-23.81-27.85
Non-Operating Income (Expense)-2.0973.84-2.027.11-3.253.00-6.422.76
Stock Option Compensation Expense2.431.211.771.571.491.071.381.11
Price To Sales Ratio189.0534.19-6.019.51---
Operating Margin-544.36-274.36-3.59-432.53-5.72---
Net Margin-941.20-394.02-21.59-354.89-38.60---
Shares Outstanding50.8048.3948.2147.4047.1135.2134.8534.85
Market Capitalization1,678.651,118.52222.84235.56342.97176.46127.72132.28

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments61.9551.5083.1644.1795.43145.7939.3941.3956.69
Short Term Receivables8.678.539.055.754.424.759.396.125.88
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.073.624.265.965.982.713.001.251.20
Total Current Assets73.7063.6596.4855.88105.83153.2551.7848.7663.77
Net Property, Plant & Equipment5.365.736.917.609.3110.1010.543.303.59
Total Investments and Advances0.000.000.000.000.000.000.000.000.60
Long-Term Note Receivable-------0.00-
Intangible Assets0.010.010.010.000.000.030.180.120.16
Other Assets0.510.420.330.310.480.490.450.440.55
Total Assets79.5869.81103.7263.79115.62163.8662.9452.6168.68
Short Term Debt Incl. Current Port. of LT Debt5.065.105.554.879.335.961.220.570.92
Accounts Payable7.734.647.404.275.688.698.727.446.18
Income Tax Payable0.260.560.500.380.290.350.240.210.28
Other Current Liabilities54.5050.7341.6530.9726.608.305.925.043.85
Total Current Liabilities67.5461.0355.0940.4941.9023.3016.1013.2611.23
Long Term Debt106.8947.6150.3151.8843.0053.9748.7622.894.75
Provision for Risks Charges0.600.450.360.290.360.510.370.380.28
Other Liabilities3.7828.760.000.000.000.000.000.000.00
Total Liabilities178.80137.85105.7692.6585.2777.7765.2336.5316.26
Non-Equity Reserves0.000.000.000.000.000.000.000.00-
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-99.22-68.04-2.04-28.8630.3586.09-2.2916.0852.41
Total Shareholders Equity-99.22-68.04-2.04-28.8630.3586.09-2.2916.0852.41
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-99.22-68.04-2.04-28.8630.3586.09-2.2916.0852.41
Total Liabilities & Stockholders Equity79.5869.81103.7263.79115.62163.8662.9452.6168.68
Book Value Per Share-2.05-1.44-0.04-0.830.872.50-0.100.822.67
Tangible Book Value Per Share-2.05-1.44-0.04-0.830.872.50-0.110.812.66
Full-Time Employees971081021021009011010285
Price to Book Ratio-43.86-5.83-4.3770.679.296.60-15.20--
Return on Assets-36.20-84.94-51.24-66.83-39.76-33.77-98.64-59.03-58.69
Return on Equity----8,044.82-95.42-91.38-826.38-104.53-83.64
Return on Invested Capital-352.77--88.91-260.50-75.73-27.34-122.64-91.87-51.58
Quick Ratio1.091.041.751.382.536.583.223.685.68
Current Ratio1.091.041.751.382.536.583.223.685.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-62.06-27.04-73.70-42.92-59.95-55.56-38.29-56.99-35.80
Depreciation1.791.691.751.641.581.842.001.980.73
Other Funds (Non Cash)24.09-10.2534.299.5316.003.43-2.4710.243.14
Funds from Operations-36.18-35.61-37.66-31.76-42.37-50.29-38.76-44.77-31.93
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-10.89-3.8415.4510.722.4213.646.57-1.701.27
Cash from Operating Activities-47.08-39.45-22.21-21.03-39.96-36.65-32.19-46.47-30.66
Capital Expenditures-1.20-0.62-0.92-0.36-0.10-0.28-0.12-1.62-0.60
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.060.000.000.000.000.000.00-0.00
Purchase or Sale of Investments-0.03-0.04-0.12-0.010.24-0.01-0.01-0.020.68
Purchase of Investments-0.03-0.04-0.12-0.010.00-0.01-0.01-0.020.00
Sale Or Maturity of Investments0.000.000.000.000.240.000.000.000.68
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.17-0.65-1.03-0.380.15-0.29-0.13-1.630.08
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock97.110.860.0062.020.00-0.36117.7632.91-0.26
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock97.110.860.0062.020.00-0.36117.7632.91-0.26
Proceedsfrom Stock Options83.600.860.0062.020.00-0.41117.7531.43-0.33
Issuance or Reduction of Debt, Net44.1344.45-3.33-3.05-3.83-3.3511.5115.1117.78
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities141.8743.95-4.4958.11-4.98-4.78128.2146.8317.52
Exchange Rate Effect0.56-0.450.10-0.060.090.08-0.070.030.06
Net Change in Cash94.183.40-27.6336.64-44.70-41.6495.82-1.24-12.99
Free Cash Flow-48.27-40.05-23.12-21.39-40.05-36.92-32.30-47.69-31.15
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S12023S22023S1
Cash & Short Term Investments126.7861.9533.8371.0983.1623.60
Short Term Receivables10.718.6710.7412.709.0510.65
Inventories0.000.000.000.000.000.00
Other Current Assets3.683.072.262.434.262.44
Total Current Assets141.1873.7046.8286.2396.4836.69
Net Property, Plant & Equipment5.045.365.716.336.917.07
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.010.010.020.010.010.00
Other Assets0.500.510.480.330.330.32
Total Assets146.7279.5853.0392.90103.7244.08
Short Term Debt Incl. Current Port. of LT Debt36.665.065.565.365.5510.88
Accounts Payable7.057.734.965.117.409.60
Income Tax Payable0.630.260.490.770.500.42
Other Current Liabilities53.9154.5062.9949.3441.6533.49
Total Current Liabilities98.2567.5474.0060.5755.0954.39
Long Term Debt85.23106.8954.5947.3450.3148.04
Other Liabilities0.783.784.827.940.000.00
Total Liabilities184.89178.80133.97116.24105.76102.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-38.17-99.22-80.94-23.34-2.04-58.68
Total Shareholders Equity-38.17-99.22-80.94-23.34-2.04-58.68
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-38.17-99.22-80.94-23.34-2.04-58.68
Total Liabilities & Stockholders Equity146.7279.5853.0392.90103.7244.08
Book Value Per Share-0.75-2.05-1.68-0.49-0.04-1.67
Tangible Book Value Per Share-0.75-2.05-1.68-0.49-0.04-1.67
Price to Book Ratio-43.86-13.77-9.61-115.71-4.37-3.04
Return on Assets-61.74---52.84-51.24-95.80
Return on Invested Capital-84.99-282.65--98.51-26.00-
Quick Ratio1.441.090.631.421.750.67
Current Ratio1.441.090.631.421.750.67

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S12023S22023S1
Net Income-40.00-22.07-5.88-23.64-12.58-30.36
Depreciation0.920.870.870.850.840.80
Other Funds (Non Cash)18.495.60-16.202.685.104.43
Funds from Operations-20.59-15.59-21.20-20.11-6.65-25.13
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.11-5.791.8213.244.596.14
Cash from Operating Activities-25.70-21.38-19.38-6.87-2.05-18.99
Capital Expenditures-0.73-0.46-0.17-0.53-0.01-0.35
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.060.000.000.000.000.00
Purchase or Sale of Investments0.00-0.03-0.00-0.01-0.01-0.00
Purchase of Investments0.00-0.03-0.00-0.01-0.01-0.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.67-0.50-0.18-0.54-0.02-0.35
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock96.230.880.000.0062.050.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock96.230.880.000.0062.050.00
Proceedsfrom Stock Options82.710.880.000.0062.050.00
Issuance or Reduction of Debt, Net-1.8048.03-2.10-1.65-1.49-1.56
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities93.7348.14-2.72-2.3160.13-1.99
Exchange Rate Effect0.460.09-0.560.05-0.03-0.02
Net Change in Cash67.8226.36-22.85-9.6758.02-21.35
Free Cash Flow-26.43-21.84-19.55-7.40-2.06-19.34

Revenue breakdown

Other Sales2024: 6.41M 2025: 7.85M
Services2024: -18.97M 2025: 25.58M
France2024: -12.56M 2025: 33.43M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.41%0.2M41.7M149.05K
2026-10-150.47%0.2M41.6M152.35K
2026-09-300.35%0.1M41.6M143.75K
2026-09-150.42%0.2M41.5M135.09K
2026-08-310.36%0.1M41.5M124.65K
2026-08-140.32%0.1M41.5M100.50K
2026-07-310.24%0.1M41.5M97.94K
2026-07-150.21%0.1M40.7M85.48K
2026-06-300.13%0.1M40.7M80.13K
2026-06-150.16%0.1M40.7M76.77K
2026-05-290.08%0.0M40.2M78.17K
2026-05-150.21%0.1M38.5M73.84K
2026-04-300.10%0.0M38.5M59.90K
2026-04-150.03%0.0M38.5M48.93K
2026-03-310.07%0.0M38.5M44.99K
2026-03-130.04%0.0M38.5M36.71K
2026-02-270.04%0.0M38.5M30.50K
2026-02-130.17%0.1M38.5M36.21K
2026-01-300.08%0.0M38.5M42.56K
2026-01-150.08%0.0M38.5M62.79K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5018.0022.900.007.5060.000.000.919-0.4220.008
call15.0015.5020.400.006.3140.000.000.895-0.4290.009
call17.5013.0017.900.005.3390.000.000.870-0.4250.011
call20.0010.5015.400.004.5100.000.000.842-0.4130.012
call22.508.0012.900.003.7810.000.000.811-0.3950.014
call25.005.5010.400.003.1210.000.000.773-0.3710.015
call30.001.005.504.901.96911.000.000.669-0.3320.019
call35.000.004.800.002.7070.000.000.528-0.3060.021
call40.000.004.400.003.2680.000.000.454-0.3770.020
call45.000.004.100.003.6960.000.000.404-0.4160.020
put12.500.004.100.009.6450.000.00-0.081-0.4180.008
put15.000.004.100.008.1140.000.00-0.104-0.4250.009
put17.500.004.100.006.9010.000.00-0.129-0.4210.011
put20.000.004.100.005.8880.000.00-0.157-0.4090.012
put22.500.004.100.005.0110.000.00-0.188-0.3910.014
put25.000.004.100.004.2300.000.00-0.225-0.3670.015
put30.000.004.800.003.2090.000.00-0.327-0.3300.019
put35.001.506.000.002.3510.000.00-0.474-0.3060.020
put40.006.0010.500.002.6050.000.00-0.547-0.3770.020
put45.0011.1015.500.003.1670.000.00-0.596-0.4160.020

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-24SEC
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-08-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-25SEC
2026-08-13SCHEDULE 13G/ASEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-30SEC
2026-07-29SCHEDULE 13G/ASEC
2026-06-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-05SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-05-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-26SEC
2026-05-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-26SEC
2026-05-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-22SEC
2026-05-22FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-05-22424B5SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-21SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-21SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-21SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-20SEC
2026-05-21FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-05-21FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-05-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-20SEC
2026-05-20424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JOHNSON & JOHNSON11.11%
MORGAN STANLEY0.10%
JANE STREET GROUP, LLC0.06%
HRT FINANCIAL LP0.05%
XTX Topco Ltd0.03%
Optiver Holding B.V.0.03%
MARSHALL WACE, LLP0.02%
CITADEL ADVISORS LLC0.01%
UBS Group AG0.01%
BNP PARIBAS FINANCIAL MARKETS0.01%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.01%
ActivePassive International Equity ETF0.00%
Steward Values Enhanced International Fund0.00%

OakChart. NBTX. Cached 15 minutes.

Some panels did not load: insider.